My OB wants me to stop Wilson disease treatment in pregnancy — is that safe?

Your hepatologist is right. The guidance from both major liver disease societies — American (AASLD) and European (EASL) — is unambiguous: Wilson disease treatment must continue throughout pregnancy.¹² Stopping all treatment is not a safe option and is associated with serious, potentially fatal maternal outcomes including acute liver failure.

Your obstetrician almost certainly has the best intentions, and this kind of conflict between specialties is common in Wilson disease pregnancies. OBs and maternal-fetal medicine specialists are appropriately cautious about medications in pregnancy, but Wilson disease is one of the situations where discontinuing treatment carries far greater risk than continuing it — and the evidence supports this clearly.³ What you need is not a choice between the two doctors, but a conversation that brings them into alignment. You need a joint management plan.

Why stopping is dangerous

When Wilson disease is being treated, copper is either being actively removed from the body (chelators — penicillamine and trientine) or its absorption is being blocked (zinc). Take away that treatment, and copper begins reaccumulating immediately. Pregnancy itself adds another variable: the physiological changes of pregnancy alter copper metabolism, and some evidence suggests maternal copper handling changes in ways that can accelerate copper release from tissue.⁴

Cases of acute hepatic decompensation and acute liver failure have been documented in pregnant women with Wilson disease who discontinued treatment — sometimes rapidly, within weeks of stopping.³ The liver failure in this context is particularly dangerous because it occurs against the backdrop of pregnancy, complicating both maternal and fetal management. The lesson from these cases is consistent: stopping all treatment in pregnancy is not a conservative choice — it is a high-risk one.

This is why the AASLD 2022 Practice Guidance states explicitly that treatment should be continued throughout pregnancy, with the focus being on which treatment is most appropriate rather than whether to treat at all.¹

The actual question: which medication during pregnancy?

The real clinical decision is not whether to continue treatment, but how — and this is where different medications carry different profiles in pregnancy:

Zinc

Zinc salts are generally considered the preferred option during pregnancy for women who are already well-controlled and clinically stable.¹² Zinc blocks copper absorption rather than mobilising stored copper, which makes it pharmacologically gentler. It crosses the placenta minimally and has a long track record of use in pregnancy without significant fetal harm. For a woman entering pregnancy in a stable, well-controlled state, many specialists recommend switching to or continuing zinc for the duration of pregnancy.⁵

Trientine (triethylene tetramine)

Trientine is considered compatible with pregnancy for women who cannot safely switch to zinc — for example, those with significant hepatic copper accumulation who need active chelation rather than merely blocking absorption. A retrospective analysis by Pfeiffenberger and colleagues found that women who maintained treatment (including trientine) throughout pregnancy had significantly better outcomes than those who discontinued.³ Trientine dose may be adjusted (some specialists reduce the dose slightly to avoid over-chelation of the fetus), but it is not discontinued.

Penicillamine

Penicillamine has the longest track record in pregnancy and has been used successfully for decades.³ However, it does carry a risk of connective tissue complications in the fetus at higher doses, and some guidelines recommend a dose reduction in the third trimester if penicillamine is being used. It is not stopped outright. The Brewer group’s data on zinc in pregnancy and the Pfeiffenberger cohort both demonstrate that outcomes are generally good when treatment is maintained, regardless of which agent is used.⁵⁶

Medication	Use in pregnancy	Key considerations
Zinc	First choice for stable, controlled patients	Minimal fetal exposure; blocks absorption rather than mobilising copper
Trientine	Acceptable for those needing chelation	Dose may be adjusted; not discontinued
Penicillamine	Acceptable with monitoring	Dose reduction in third trimester sometimes recommended

How to resolve the conflict between your doctors

This is not a situation where you should be left in the middle choosing which specialist to follow. A few practical steps:

Ask your hepatologist to contact your obstetrician directly. A brief letter or phone call explaining the specific risks of stopping treatment in Wilson disease pregnancy — with references to the AASLD 2022 guidance and the Pfeiffenberger 2018 data — is often sufficient. Most OBs, once they understand the maternal mortality data associated with stopping, are no longer advocating for it.

Request a referral to a maternal-fetal medicine (MFM) specialist. MFM specialists manage high-risk pregnancies and are more familiar than general obstetricians with rare metabolic diseases. A single consultation with an MFM specialist who has reviewed your Wilson disease history may resolve the impasse entirely.

Seek a Wilson disease centre with pregnancy experience. Several centres in North America and Europe have managed large numbers of Wilson disease pregnancies. A consultation (even via telemedicine) with such a centre can provide a unified recommendation that both your OB and hepatologist can work from.

Bring published evidence to appointments. The Pfeiffenberger 2018 paper in Hepatology specifically addresses this question with outcome data.³ The Reuner 2019 report from a perinatal centre describes a cohort of Wilson disease pregnancies managed with continued treatment.⁴ Your hepatologist can provide these references.

Monitoring during pregnancy

Even with treatment continuing, pregnancy management in Wilson disease requires closer monitoring than outside pregnancy — typically every 1–3 months:¹

• Liver enzymes, bilirubin, PT/INR
• 24-hour urine copper (targets adjust by trimester and by medication)
• Serum ceruloplasmin and copper
• Fetal growth scans as clinically indicated

Breastfeeding after delivery requires a separate discussion: copper and some medications pass into breast milk, and guidance on this is evolving. The Kodama 2021 study found measurable copper and drug levels in breast milk of treated mothers; your hepatologist can advise on the current recommendation for your specific medication.⁷

See also: pregnancy for a broader overview of Wilson disease in pregnancy.

This post is for patient education only. The treatment decisions described here are individual clinical judgements that depend on your specific disease status, medication, and pregnancy. Please do not stop or alter any medication without direct guidance from your treating hepatologist.

References